<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92250">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698554</url>
  </required_header>
  <id_info>
    <org_study_id>192024-046</org_study_id>
    <secondary_id>2012-003007-35</secondary_id>
    <nct_id>NCT01698554</nct_id>
  </id_info>
  <brief_title>Bimatoprost in the Treatment of Eyelash Hypotrichosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of bimatoprost solution formulation A
      compared with bimatoprost solution 0.03% (LATISSE速) and vehicle in the treatment of eyelash
      hypotrichosis (inadequate eyelashes).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigator's Assessment of Overall Eyelash Prominence as Measured by the 4-point Global Eyelash Assessment (GEA) Scale</measure>
    <time_frame>Month 4</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper Eyelash Length as Measured Using Digital Image Analysis (DIA)</measure>
    <time_frame>Month 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper Eyelash Thickness/Fullness as Measured Using DIA</measure>
    <time_frame>Month 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper Eyelash Intensity (Darkness) as Measured Using DIA</measure>
    <time_frame>Month 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Assessment of Overall Eyelash Satisfaction as Measured by the 9-item Eyelash Satisfaction Questionnaire</measure>
    <time_frame>Month 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">464</enrollment>
  <condition>Idiopathic Eyelash Hypotrichosis</condition>
  <arm_group>
    <arm_group_label>bimatoprost formulation A solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bimatoprost solution 0.03 %</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bimatoprost solution 0.03 % (LATISSE速) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle of bimatoprost formulation A solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle of bimatoprost solution 0.03 %</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost formulation A solution</intervention_name>
    <description>Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.</description>
    <arm_group_label>bimatoprost formulation A solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost solution 0.03 %</intervention_name>
    <description>Bimatoprost solution 0.03 % (LATISSE速) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.</description>
    <arm_group_label>bimatoprost solution 0.03 %</arm_group_label>
    <other_name>LATISSE速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle of bimatoprost formulation A solution</intervention_name>
    <description>Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.</description>
    <arm_group_label>vehicle of bimatoprost formulation A solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle of bimatoprost solution 0.03 %</intervention_name>
    <description>Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.</description>
    <arm_group_label>vehicle of bimatoprost solution 0.03 %</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate eyelash hypotrichosis (inadequate eyelashes)

        Exclusion Criteria:

          -  Damage to eyelid area (scarring) that may prevent growth of eyelashes

          -  Active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe
             dry eye)

          -  Eye or eyelid surgery (including laser, refractive, intraocular filtering surgery,
             blepharoplasty) during the 3 months prior to screening

          -  Current eyelash implants of any kind

          -  Eyelash tint or dye application within 2 months of baseline

          -  Eyelash extensions application within 3 months of baseline

          -  Use of eyelash growth products within 6 months of baseline

          -  Treatments that may affect hair growth (minoxidil, cancer chemotherapeutic agents,
             etc) within 6 months prior to baseline
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>October 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotrichosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
